NCT04311177View on ClinicalTrials.gov

Losartan for Patients With COVID-19 Not Requiring Hospitalization

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Corona Virus InfectionAcute Respiratory Distress SyndromeSARS-CoV Infection
Interventions
DRUG

Losartan

Losartan; 25 mg daily; oral administration

OTHER

Placebo

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Trial Locations (4)

55415

Hennepin County Medical Center, Minneapolis

Mayo Clinic Health System, Rochester

55455

M Health Fairview University of Minnesota Medical Center, Minneapolis

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT04311177 - Losartan for Patients With COVID-19 Not Requiring Hospitalization | Biotech Hunter | Biotech Hunter